Diversified Healthcare Trust
DHC- Exchange
- Nasdaq
- Industry
- Real Estate Investment Trusts
- SEC CIK
- 0001075415
No open-market purchases or sales by Diversified Healthcare Trust insiders were filed in the last 90 days; 242 institutions reported holding it in 13F filings for Q2 2026, worth $1.91B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 3, 2026, 1:11 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 14, 2026 | Feb 25, 2025 | Feb 26, 2024 | Mar 1, 2023 | Feb 23, 2022 |
| Revenue | $1.54B | $1.50B | $1.41B | $1.28B | $1.38B |
| Selling, general and administrative | $45.5M | $26.5M | $26.1M | $26.4M | $34.1M |
| Interest expense | – | – | $191.8M | $209.4M | $255.8M |
| Income tax | $1.74M | $467.0K | $445.0K | $710.0K | $1.43M |
| Net income | -$285.9M | -$370.3M | -$293.6M | -$15.8M | $174.5M |
| EPS, basic | $-1.19 | $-1.55 | $-1.23 | $-0.07 | $0.73 |
| EPS, diluted | $-1.19 | $-1.55 | $-1.23 | $-0.07 | $0.73 |
| Weighted shares, basic | 240.3M | 239.5M | 238.8M | 238.3M | 238.0M |
| Weighted shares, diluted | 240.3M | 239.5M | 238.8M | 238.3M | 238.0M |
| Margins and growth | |||||
| Net margin | -18.6% | -24.8% | -20.8% | -1.2% | 12.6% |
| Revenue growth, year over year | +2.8% | +6.0% | +9.9% | −7.2% | −15.2% |
| Net income growth, year over year | – | – | – | −109.0% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 14, 2026 | Feb 25, 2025 | Feb 26, 2024 | Mar 1, 2023 | Feb 23, 2022 |
| Cash and equivalents | $105.4M | $144.6M | $245.9M | $658.1M | $634.8M |
| Intangible assets | $20.7M | $26.3M | $33.9M | $45.4M | $48.7M |
| Total assets | $4.36B | $5.14B | $5.45B | $6.00B | $6.62B |
| Long-term debt | $2.44B | $3.05B | – | – | – |
| Total liabilities | $2.70B | $3.18B | $3.11B | $3.36B | $3.96B |
| Shareholders' equity | $1.67B | $1.96B | $2.34B | $2.64B | $2.66B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 14, 2026 | Feb 25, 2025 | Feb 26, 2024 | Mar 1, 2023 | Feb 23, 2022 |
| Operating cash flow | -$19.6M | $112.2M | $10.5M | -$40.4M | -$63.3M |
| Capital expenditures | $146.8M | $201.7M | $235.0M | $299.4M | $227.6M |
| Free cash flow | -$166.4M | -$89.5M | -$224.5M | -$339.7M | -$290.9M |
| Depreciation and amortization | $261.9M | $285.0M | $284.1M | $239.3M | $271.1M |
| Stock-based compensation | $3.41M | $2.75M | $1.84M | $1.73M | $1.96M |
| Dividends paid | $9.66M | $9.63M | $9.60M | $9.57M | $9.54M |
| Share buybacks | $1.15M | $904.0K | $393.0K | $171.0K | $383.0K |
| Investing cash flow | $483.6M | -$187.0M | -$202.1M | $387.7M | $242.7M |
| Financing cash flow | -$492.0M | -$22.3M | -$249.7M | -$676.0M | $746.7M |
| Net change in cash | -$28.1M | -$97.1M | -$441.3M | -$328.6M | $926.1M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 242.5M | +0.2% | SEC |
| Jul 31, 2026 | 242.1M | +0.3% | SEC |
| Apr 30, 2026 | 242.1M | +0.4% | SEC |
| Feb 20, 2026 | 242.1M | +0.4% | SEC |
| Nov 1, 2025 | 242.1M | +0.4% | SEC |
| Aug 1, 2025 | 241.4M | +0.3% | SEC |
| Apr 30, 2025 | 241.3M | +0.4% | SEC |
| Feb 21, 2025 | 241.3M | +0.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.